NMRA 335140 for Depression
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new medication called NMRA 335140 to see if it can help people with Major Depressive Disorder feel less depressed. The study involves an initial evaluation and a treatment phase where participants will receive either the medication or an inactive substance. The medication likely works by changing brain chemicals that affect mood.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What safety data is available for NMRA 335140 (Navacaprant) in treating depression?
The provided research does not contain specific safety data for NMRA 335140 (Navacaprant) or its other names like BTRX-140, BTRX-335140, CYM-53093, NMRA-140. The studies focus on other NMDA antagonists and their safety profiles in different contexts, such as stroke and neurosurgery patients, or as adjuncts in depression treatment. Therefore, no direct safety data for NMRA 335140 is available in the provided research.12345
Is the drug NMRA 335140 a promising treatment for depression?
What data supports the idea that NMRA 335140 for Depression is an effective drug?
The available research does not provide any data supporting the effectiveness of NMRA 335140 for treating depression. The studies mentioned focus on other treatments and drugs, such as TC-5214, nitrous oxide, brexpiprazole, and ketamine, but do not include any information or results related to NMRA 335140. Therefore, there is no evidence from the provided information to suggest that NMRA 335140 is an effective treatment for depression.1011121314
Are You a Good Fit for This Trial?
This trial is for individuals with Major Depressive Disorder (MDD) confirmed by a clinical interview, experiencing symptoms for more than 4 weeks but less than 12 months. Participants must have a significant level of depression severity and haven't had two or more failed antidepressant treatments for the current episode. Excluded are those with certain other mental disorders, recent substance abuse, or serious suicidal risk.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either NMRA-335140 or placebo for 6 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- NMRA 335140
Find a Clinic Near You
Who Is Running the Clinical Trial?
Neumora Therapeutics, Inc.
Lead Sponsor